Pfizer Oncology will present nearly 30 abstracts highlighting research in new and established pathways, including inhibition of Hedgehog signaling (PF-04449913); dual inhibition of PI3K/mTOR (phosphatidylinositol 3-kinase/mammalian target of rapamycin)(PF-04691502); and cancer stem cell-based targets. Data from this research as well as data from studies involving investigational compounds, including crizotinib, an oral first-in-class compound that inhibits the anaplastic lymphoma kinase, or ALK, will be presented at the upcoming American Association for Cancer Research (AACR) 102nd Annual Meeting 2011 in Orlando, FL from April 2-6.
"Pfizer has exciting research underway in its early pipeline providing the preclinical rationale for potential future treatment options for cancer patients," said Robert Abraham, PhD, senior vice president and chief scientific officer, Oncology Research Unit, Pfizer Worldwide Research and Development. "The data we will present at AACR are focused on the biology and basic science behind cancer and tumor growth, which may ultimately help us to improve patient outcomes."
At AACR, Pfizer will present preclinical data from emerging fields of cancer research, including:
Pfizer & Stand Up to Cancer
Pfizer is proud to be a Stand Up to Cancer (SU2C) donor. SU2C is a cutting edge initiative created to accelerate groundbreaking cancer research, for which AACR is the scientific partner.
Triple-negative breast cancer patients with high immune cell levels have lower relapse risk after surgery